Huang J, Ngai CH, Deng Y, et al. Cancer incidence and mortality in asian countries: a trend analysis. Cancer Control. 2022;29:10732748221095956. https://doi.org/10.1177/10732748221095955.

Article  PubMed  PubMed Central  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.

Article  PubMed  Google Scholar 

Huang J, Deng Y, Tin MS, et al. Distribution, risk factors, and temporal trends for lung cancer incidence and mortality: a global analysis. Chest. 2022;161(4):1101–11. https://doi.org/10.1016/j.chest.2021.12.655.

Article  PubMed  Google Scholar 

Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19(9):495–509. https://doi.org/10.1038/s41568-019-0179-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferreira CG, Reis MX, Veloso GGV. Editorial: molecular genetic testing and emerging targeted therapies for non-small cell lung cancer. Front Oncol. 2023;13:1308525. https://doi.org/10.3389/fonc.2023.1308525.

Article  PubMed  PubMed Central  Google Scholar 

Yamamoto K, Toyokawa G, Kozuma Y, Shoji F, Yamazaki K, Takeo S. ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: a case report. Thorac Cancer. 2021;12(11):1761–4. https://doi.org/10.1111/1759-7714.13962.

Article  PubMed  PubMed Central  Google Scholar 

Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management [published correction appears in Nat Rev Clin Oncol. 2022;19(11):744. https://doi.org/10.1038/s41571-022-00680-8]. Nat Rev Clin Oncol. 2022;19(8):499–514. https://doi.org/10.1038/s41571-022-00639-9.

Cameron LB, Hitchen N, Chandran E, et al. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev. 2022;1(1): CD13453. https://doi.org/10.1002/14651858.CD013453.pub2.

Article  Google Scholar 

Solomon BJ, Bauer TM, Mok TSK, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11(4):354–66. https://doi.org/10.1016/S2213-2600(22)00437-4.

Article  CAS  PubMed  Google Scholar 

Peng L, Zhu L, Sun Y, et al. Targeting ALK rearrangements in NSCLC: current state of the Art. Front Oncol. 2022;12:863461. https://doi.org/10.3389/fonc.2022.863461.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Golding B, Luu A, Jones R, et al. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer. 2018;17:52. https://doi.org/10.1186/s12943-018-0810-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28(1):70–81. https://doi.org/10.1016/j.ccell.2015.05.010.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bearz A, Martini JF, Jassem J, et al. Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced NSCLC in relation to EML4::ALK variant type and ALK with or without tp53 mutations. J Thorac Oncol. 2023;18(11):1581–93. https://doi.org/10.1016/j.jtho.2023.07.023.

Article  CAS  PubMed  Google Scholar 

Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018–29. https://doi.org/10.1056/NEJMoa2027187.

Article  CAS  PubMed  Google Scholar 

Shaw AT, Solomon BJ, Besse B, et al. ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. J Clin Oncol. 2019;37(16):1370–9. https://doi.org/10.1200/JCO.18.02236.

Article  PubMed  PubMed Central  Google Scholar 

Bauer TM, Felip E, Solomon BJ, et al. Clinical management of adverse events associated with lorlatinib. Oncologist. 2019;24(8):1103–10. https://doi.org/10.1634/theoncologist.2018-0380.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reed M, Rosales AS, Chioda MD, Parker L, Devgan G, Kettle J. Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners. Adv Ther. 2020;37(6):3019–30. https://doi.org/10.1007/s12325-020-01365-3.

Article  PubMed  PubMed Central  Google Scholar 

Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study [published correction appears in Lancet Oncol. 2019;20(1):e10. https://doi.org/10.1016/S1470-2045(18)30927-6]. Lancet Oncol. 2018;19(12):1654–1667. https://doi.org/10.1016/S1470-2045(18)30649-1.

Prinz U, Nutzinger DO, Schulz H, Petermann F, Braukhaus C, Andreas S. Comparative psychometric analyses of the SCL-90-R and its short versions in patients with affective disorders. BMC Psychiatry. 2013;13:104. https://doi.org/10.1186/1471-244X-13-104.

Article  PubMed  PubMed Central  Google Scholar 

Richter P, Werner J, Heerlein A, Kraus A, Sauer H. On the validity of the beck depression inventory: a review. Psychopathology. 1998;31(3):160–8. https://doi.org/10.1159/000066239.

Article  CAS  PubMed  Google Scholar 

Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The mini-cog: a cognitive “vital signs” measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 2000;15(11):1021–7. https://doi.org/10.1002/1099-1166(200011)15:113.0.co;2-6.

Article  CAS  PubMed  Google Scholar 

Barata F, Aguiar C, Marques TR, Marques JB, Hespanhol V. Monitoring and managing lorlatinib adverse events in the Portuguese clinical setting: a position paper. Drug Saf. 2021;44(8):825–34. https://doi.org/10.1007/s40264-021-01083-x.

Article  CAS  PubMed  Google Scholar 

Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies. CTCAE versión 5.0. Actas Dermosifiliogr. 2021;112(1):90–2. https://doi.org/10.1016/j.ad.2019.05.009.

Article  CAS  PubMed  Google Scholar 

Solomon BJ, Bauer TM, Ignatius Ou SH, et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study. J Clin Oncol. 2022;40(31):3593–602. https://doi.org/10.1200/JCO.21.02278.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soo RA, Huat Tan E, Hayashi H, et al. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: subgroup analysis of a global phase 2 trial. Lung Cancer. 2022;169:67–76. https://doi.org/10.1016/j.lungcan.2022.05.012.

Article  CAS  PubMed  Google Scholar 

Lu C, Yu R, Zhang C, et al. Protective autophagy decreases lorlatinib cytotoxicity through Foxo3a-dependent inhibition of apoptosis in NSCLC. Cell Death Discov. 2022;8(1):221. https://doi.org/10.1038/s41420-022-01027-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shimizu Y, Okada K, Adachi J, et al. GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer. NPJ Precis Oncol. 2022;6(1):16. https://doi.org/10.1038/s41698-022-00260-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aboubakr M, Elshafae SM, Abdelhiee EY, et al. Antioxidant and Anti-inflammatory potential of thymoquinone and lycopene mitigate the chlorpyrifos-induced toxic neuropathy. Pharmaceuticals. 2021;14(9):940. https://doi.org/10.3390/ph14090940.